DaSH Global in collaboration with Mesothelioma UK have undertaken a prospective cross-sectional study in the UK collecting both Clinical and Patient Reported Outcomes data from a total of 503 Mesothelioma patients.

It has been good to take a look back at an article I contributed to with NICE and IQWIG in 2014: “Is Pharma doing enough to maximise real world evidence?”. It was interesting to compare “where we were then” to “where we are now” – or should we say, “where we want to be now”?